



Normalization of disrupted clock gene expression in males with tetraplegia. 2 
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Study design Crossover double blind, randomized placebo-controlled trial. 28 
Objective Circadian oscillators are located both in the brain and in peripheral organs. 29 
Melatonin, the main brain-derived hormone governing circadian variations, is highly 30 
associated with daylight patterns. However, in subjects with tetraplegia the melatonin levels 31 
are blunted. Here we studied peripheral oscillators in peripheral blood mononuclear cells 32 
(PBMCs) in males with tetraplegia by examining how exogenous melatonin may influence 33 
the expression of clock gene mRNAs.  34 
Setting Sunnaas Rehabilitation Hospital, Nesoddtangen, Norway. 35 
Methods Six males with tetraplegia received 2 mg of melatonin or placebo 4 days before the 36 
study period. We also included six able-bodied men sleeping or kept awake during the night. 37 
Plasma samples were collected four times during a 24-h period. The mRNA expression levels 38 
of the clock genes PER1, PER2, BMAL1 and REV-ERBα were quantified in PBMCs using 39 
quantitative RT-PCR.  40 
Results The mRNA expression levels of PER-1 and -2 and REV-ERBα were increased at 41 
04:00 h compared to the able-bodied controls (p < 0.05). Melatonin supplementation changed 42 
mRNA peak-time towards the time of supplementation. 43 
Conclusions Several peripheral clock genes displayed distorted expression levels in 44 
tetraplegia. Supplementation with melatonin changed the mRNA expression levels of these 45 
genes towards those observed among able-bodied. 46 
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In all species many biochemical, physiological, and behavioural processes oscillate with a 24-52 
h period. These rhythms are driven by endogenous circadian clocks, which function through 53 
interacting with positive and negative transcriptional/translational feedback loops. The main 54 
murine genes of the negative-feedback loop are the Pers and Crys, whereas Clock and Bmal1, 55 
coding for two basic helix-loop-helix transcriptional activators, are important genes of the 56 
positive loop [1]. These positive and negative feedback loops are interconnected by a second 57 
loop where the transcription of Rev-Erbα and Rora, two nuclear orphan receptor genes, is 58 
regulated by Clock:Bmal1 heterodimers. Rev-Erbα and Rora compete for the same element on 59 
the Bmal1 promoter, but have opposing actions. This circadian timing system is governed by 60 
a master circadian pacemaker located in the suprachiasmatic nucleus of the anterior 61 
hypothalamus as well as peripheral oscillators located in most organs and tissues [2]. Also in 62 
humans the expression of PER1, PER2, and BMAL1 mRNAs show circadian rhythmicity in 63 
peripheral tissues (e.g. the skin and the oral mucosa), and in the peripheral blood mononuclear 64 
cells [PBMCs] [3-6]. 65 
Following a complete cervical spinal cord injury (SCI) in humans, nervous input 66 
through somatic and autonomic afferent fibres from the body below the SCI level is disrupted 67 
and the efferent sympathetic innervation of the pineal gland via the superior cervical ganglion 68 
is lacking control from higher autonomic centres. It has been hypothesized that these 69 
disrupted nervous connections abolish rhythmic melatonin production. In line with this we 70 
and others have reported blunted circadian rhythm and low blood levels of melatonin in 71 
persons with cervical SCI [7-9] and indeed, in healthy adults, melatonin levels range from 72 
approximately 10 pg/mL at the end of the light period up to 200 pg/mL near the midpoint of 73 
the dark period, whereas in tetraplegic subjects the corresponding values are closer to 2 and 74 




Melatonin has been used as a marker of the central circadian pacemaker in humans [10-77 
11], however, it is unclear how the peripheral oscillators are influenced by the absence of 78 
melatonin rhythmicity in humans with complete cervical SCI and blunted melatonin levels. 79 
To study the effect of melatonin on the circadian variations of markers of haemostasis (many 80 
of which show 24-h rhythms [7 and references therein]), we performed a cross-over double-81 
blind, randomized placebo-controlled trial of melatonin supplementation in tetraplegia [7].We 82 
could not attribute any major role of melatonin in regulating the circadian variation of a wide 83 
range of hemostatic factors [7]. However, in a previous investigation we did find melatonin to 84 
reduce peak thrombin generation [12]. Although melatonin supplementation did not change 85 
the levels of many other hemostatic factors, it could modify circadian variations of peripheral 86 
clock genes. We therefore planned for and used specially prepared blood samples (PAX gene 87 
RNA Blood collection tubes (PreAnalytiX) obtained in our randomized trial to examine the 88 
effect of melatonin supplementation on the expression of four cardinal circadian clock genes 89 
(Per1, Per2, Bmal1 and Rev-Erbα), in PBMCs sampled 4 times throughout a 24-h cycle in six 90 
tetraplegic subjects. Blood was specifically collected four times during a 24-h period, namely 91 
at 07:00, 22:00, 04:00 and 07:00 h to capture possible changes in clock gene expression levels 92 
around the time of melatonin supplementation. We also included six able-bodied subjects 93 




Subjects and design of study 96 
The study was approved by the Regional Committee for Medical Health Research Ethics in 97 
Norway and is registered with Clinicaltrials.gov identifier: NCT 01741389 and with the 98 
Norwegian Medicines Agency EUDRACT no. 2010-021212-24. Details of the study design 99 
and randomization have been described previously [7]. Briefly, we designed a cross-over 100 
double-blind, placebo-controlled trial of six tetraplegic men in addition to a control group of 101 
six able-bodied men, i.e. four study-groups: tetraplegic men given placebo, the same 102 
tetraplegic men given melatonin, and able-bodied men sleeping or kept awake during the 103 
night. During the time of the trial sunset and sunrise occurred around 07:00 and 19:00 h, 104 
respectively. The trial was performed in the south of Norway.  The tetraplegic men were 105 
invited through the hospital’s own in-patient coordinator. The able-bodied participants were 106 
all hospital staff and were invited through intranet or by direct request. The tetraplegic men 107 
were randomized to first receive 2 mg of melatonin (Circadin; Neurim Pharmaceuticals, Zug, 108 
Switzerland) or placebo (Kragerø Tablettproduksjon AS, Kragerø, Norway) daily at 22:00 h 109 
for 4 days before they were subjected to a 24-h period of blood sampling (see figure 1a). The 110 
dose of 2 mg of melatonin is recommended for the treatment of insomnia, and in a pilot study 111 
we found that this dose markedly increased the blood concentration of melatonin (data not 112 
published). Blood was collected four times during a 24-h period, namely at 07:00, 22:00, 113 
04:00 and 07:00 h. The “wash-out” period lasted 4 days in the tetraplegic group before the 114 
cross-over, which is assumed to be sufficient since the half-life of melatonin is about 35-50 115 
min, thus ensuring minimal, if any, carry-over effect. The able-bodied men were subjected to 116 
a similar two 24-h periods of blood sampling, with two weeks in-between sampling. They 117 
slept or were kept awake during the night with group-common low-intensity activities as 118 
playing computer games, table tennis or watching movies (see figure 1b). All the participants 119 
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received standardized meals at regular time-points. No other restrictions except zero alcohol 120 
intake and maximum two cups of coffee were required from the participants.  121 
 122 
Blood sampling 123 
Venous blood samples were collected in 5 ml Vacutainer vacuum tubes containing 0.5 ml 124 
buffered sodium citrate (0.129 M) (Becton-Dickinson, Plymouth, UK) and 2.5 ml PAX gene 125 
RNA Blood collection tubes (PreAnalytiX, Hombrechtikon, Switzerland). Citrated blood was 126 
kept at room temperature and immediately centrifuged at 2000 g for 15 min. Platelet-poor 127 
plasma aliquots and PAX gene RNA tubes were stored at -70 °C until assayed. All analyses 128 
were performed examiner-blind, and the samples were run in-batch using a balanced set-up 129 
with equal number of cases and controls in each run.  130 
 131 
Assays 132 
Melatonin concentrations were assayed with an ELISA-kit (Buhlmann Lab. AG, Basel, 133 
Switzerland) as described earlier [7]. For clock gene expression analysis, DNase-treated total 134 
RNA was isolated from PBMCs and used for cDNA synthesis (iScript™ cDNA synthesis kit, 135 
Biorad, Milan, Italy). cDNA was PCR-amplified in a CFX Connect Real-Time PCR Detection 136 
System [Biorad, Milan, Italy] using SsoFast EvaGreen Supermix (Biorad). The following 137 
primers were used: 138 
 139 
Per1 F: GTGCGGAGGACACTCCTG, R: TTGGCTGAGGGAGTGAGGT;  140 
Per2 F: TCGTTTGAACTGCGGTGAC, R: GTATCCATTCATGCTGGGCT;   141 
Bmal1 F: AGCCACGGTGGTGCTGGCTA, R:  AACCAATGAAGGCCCAGGATTCCAC;  142 
Rev-Erbα: F: CGCAACCTCTAGTTTGAGTCAAGGTCC, R: 143 
ACGCCACCTGTGTTGTTGTTGGA;  144 
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18S rRNA F: CGAGCCGCCTGGATACC, R:  CATGGCCTCAGTTCCGAAAA;  145 
GAPDH F: GATGACATCAAGAAGGTGGTGAAGC, R: 146 
TTCGTTGTCATACCAGGAAATGAGC;  147 
CDK4 F: ATCCCAATGTTGTCCGGCTG, R:  TGATCTCCCGGTCAGTTCGG.  148 
 149 
We used NormFinder (Aarhus University Hospital, Denmark) to evaluate and screen the 150 
following three housekeeping genes: GAPDH, CDK4 and 18S rRNA. Based on the rankings, 151 
we have chosen to normalize to the geometric mean of CDK4 and 18S, and the expression of 152 
genes of interest using the 2–ΔΔCt method (arbitrary units (AU)) [13]. We furthermore, scaled 153 
the AU values to the mean overall expression of each respective gene for every patient and 154 
time point. This allowed us to plot expression of several genes on the same graph in order to 155 
visualize the daily cycle of genes relative to their own expression level.  156 
 157 
Statistics 158 
The statistical analyses were performed with SPSS version 25.0 (Chicago, IL, USA) and the 159 
MedCalc Software (Mariakierke, Belgium). Values are given as mean absolute values with 160 
standard error of the mean (SEM) or as median (range) as appropriate. Differences in the 161 
plasma concentrations of the various parameters between the study groups were evaluated 162 
with two-ways ANOVA and Dunnett’s post hoc test, profile differences were evaluated with 163 
mixed models (time (continuous) versus group (categorical)). We considered p-values less 164 
than 0.05 to indicate statistical significance. 165 
  166 
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Statements of ethics 167 
We certify that all applicable institutional and governmental regulations concerning the 168 
ethical use of human volunteers were followed during the course of this research. 169 
 170 
Results 171 
Characteristics of the study participants 172 
The mean (range) age of the males with tetraplegia was 46 (27-60) years. Their injury level 173 
ranged from the cervical vertebra 5 to 8, all diagnosed with a complete injury according to the 174 
American Spinal Cord Injury Association International Standards For Neurological 175 
Classification of SCI [14], and the mean (range) time since injury was 18 (3-43) years. Their 176 
mean (range) body mass index (BMI) value was 25.4 (23.8-26.6) kg/m2. The corresponding 177 
values among the controls were not significantly different from the tetraplegic men; age 43 178 
(34-54) years and BMI 26.6 (20.1-35.3) kg/m2. All participants completed the study protocol 179 
except for one male with tetraplegia who withdrew from one of two 24-h blood samplings. 180 
 181 
Plasma melatonin profiles in the two study groups 182 
Fig. 2 shows the 24-h plasma melatonin levels in the four study groups. The plasma melatonin 183 
levels among the able-bodied increased in the evening (22:00 h), irrespective of whether they 184 
slept or not. A similar pattern was observed upon melatonin supplementation to the tetraplegic 185 
group, where the night-time melatonin plasma levels were elevated about 50-fold. As 186 
expected, the plasma melatonin levels remained low and unaltered in the tetraplegic group 187 
given placebo. 188 
 189 
Disrupted PBMC clock-gene rhythmicity in tetraplegia 190 
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To visualize the rhythmicity of genes and present the expression of core clock genes on 191 
a single graph for each group, mean scaling was performed and presented in figure 3. Only 192 
the sleeping able-bodied group  had a visual diurnal rhythmicity, i.e. the two 07:00 h 193 
measurement-points being similar for each of the four clock gene expression levels. In 194 
contrast, when these able-bodied were awake they had slightly downward flattened profiles 195 
for the four clock gene expression levels. The maximum mRNA expression level for the 196 
sleeping able-bodied apparently occurred at 07:00 h for Per1, Per2 and Bmal1, whereas the 197 
mRNA for Rev-Erbα had a maximum at 22:00 h. In the tetraplegic group the maximum 198 
mRNA expression level of all four clock-genes apparently occurred at 22:00 h in the 199 
melatonin-supplemented and at 04:00 h in the placebo-supplemented group. We examined the 200 
overall rhythm using mixed model (time versus group) analysis in the four study groups and 201 
found that the tetraplegia group receiving placebo had a different profile compared to the 202 
able-bodied group (awake) for BMAL1 and PER-1 expression (p = 0.01 and p = 0.002, 203 
respectively).   Males with tetraplegia receiving placebo had a different mRNA expression 204 
profile for all clock gene investigated than the same males receiving melatonin (Rev-Erbα: p 205 
= 0.001, Bmal1: p = 0.03 Per1: p = 0.02, Per2: p = 0.004). There were no other significant 206 
differences in any of the other mRNA levels or profiles of the four clock genes among other 207 
study-group comparisons. 208 
 209 
 We next examined the mRNA expression levels of the clock genes separately among 210 
the four study groups (Fig. 4). We observed increased Per1, Per2 and and Rev-Erbα mRNA 211 
expression levels at 04:00 h in the tetraplegic group receiving placebo compared to sleeping 212 
able-bodied (p = 0.04, p = 0.03 and p = 0.02, respectively). However, the variation (SEM) of 213 
mRNA expression levels in both tetraplegic groups (placebo or melatonin) was large. The 214 
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mRNA expression levels of BMAL1 remained unchanged (p > 0.05) among the four study 215 
groups.  216 
Discussion 217 
To our knowledge, this is the first study of mRNA expression levels of the clock genes Per1, 218 
Per2, Bmal1 and Rev-Erbα in males with tetraplegia, a condition leading to disrupted efferent 219 
input to the pineal gland from the superior cervical ganglion and thus blunted plasma 220 
melatonin levels. Our results suggest disrupted peripheral clock regulation in males with 221 
cervical SCI. In line with this we found that the tetraplegic groups receiving placebo had 222 
increased Per1, Per2 and Rev-Erbα expression levels at 04:00 h compared to awake able-223 
bodied controls. Furthermore, the melatonin supplementation changed the expression profile 224 
in the tetraplegic group by changing the maximum value from 04:00 h to 22:00 h, i.e. towards 225 
the time point of supplementation of melatonin. Thus the males with SCI receiving melatonin 226 
behaved more like the able-bodied males staying awake overall, with lower expression of all 227 
clock genes measured at 07:00 h in contrast to the able-bodied sleep group. This may be a 228 
result of clearance of melatonin in the SCI group related to the 50 times higher plasma levels 229 
of melatonin. 230 
It is well known that in addition to the disrupted efferent input to the suprachiasmatic 231 
nucleus, tetraplegic subjects have a low-grade chronic inflammation [15]. Inflammation has 232 
been shown to disrupt the expression of clock genes [16]. Our results showing reduced clock-233 
gene mRNA levels in some of the tetraplegic subjects are in accordance with other studies of 234 
PCBMs during ongoing inflammation and disease processes [17]. For example, patients with 235 
chronic lymphatic leukemia have significantly down-regulated expression of both melatonin 236 
plasma levels and mRNA of clock genes in peripheral blood (Bmal1, Per1 and Per2) [18]. 237 
Sleep deprivation also leads to decreased clock gene expression levels [19, 20], which we also 238 
found among some of our able-bodied study subjects. 239 
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On the other hand increased clock-gene mRNA expression levels in pathological 240 
conditions have been reported, e.g. a study found increased mRNA Bmal1 expression levels 241 
in prostate cancer cells [21]. Furthermore, these authors also reported that melatonin 242 
supplementation reversed and normalized the expression levels [21], i.e. similar to our 243 
findings showing a shift in the peak expression closer to melatonin supplementation. An 244 
increase in clock gene mRNA expression could be explained by melatonin receptor 245 
hypersensitivity in tetraplegia. For example, hypersensitive receptors in various organs after a 246 
SCI are recognised as parts of the mechanism behind vascular autonomic dysreflexia and 247 
changes of bladder function [22-23].  248 
Our findings with large inter-individual variation in the mRNA expression levels may 249 
mirror the heterogeneity of the SCI among the study participants and the complex feedback 250 
system of peripheral oscillators in humans [24]. Regulators other than melatonin, e.g. food 251 
and social activities, may also affect peripheral clock genes differently in subjects with SCI 252 
compared with able-bodied. Disruption of rhythms has been shown to lead to a variety of 253 
conditions including sleeping-disorders, depression and cancer [25], conditions found to be 254 
more frequent in SCI [25-29]. A dysregulated peripheral clock in tetraplegia may be an 255 
contributing factor of the increased risk of such disorders and indeed there is evidence of that 256 
the use of Circadin (melatonin) over prolonged period of time has a positive effect on sleep 257 
related disturbances in elderly people with low melatonin levels (30)  258 
Despite the low number of participants, our study was robustly designed and the study 259 
subjects were carefully monitored under standardized conditions during the 24-h study period. 260 
The washout time for plasma or brain drug levels is not necessarily the same as for the 261 
downstream effects on receptor pathways and gene translation and/or transcription. Our study 262 
design was not designed to observe these downstream effects.  In-hospital-induced stress can 263 
modify clock gene expressions [31], but this effect should have been minimized by the double 264 
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blinded and randomized cross-over design. Moreover, the tetraplegic group was rather 265 
uniform as only males were included and they all had a complete and stable, long-standing 266 
injury (> 3 years). Importantly, the tetraplegic and able-bodied subjects were matched 267 
regarding gender, age and BMI.  268 
Conclusions  269 
To our knowledge this is the first study to describe disrupted 24-h clock gene expressions 270 
PBMCs in males with tetraplegia. Our main result was that tetraplegic males receiving 271 
placebo have increased Per1, Per2 and Rev-Erbα mRNA expression levels in the early 272 
morning compared with able-bodied. Specifically, melatonin supplementation for four days 273 
changed mRNA expression profile in PBMCs in tetraplegia by shifting the peak expression 274 
towards the time point of melatonin supplementation. More studies in larger SCI patient 275 
cohorts are needed to map the regulatory function of melatonin on peripheral clock genes in 276 
various organs.  277 
  278 
14 
 
Acknowledgements  279 
We are grateful to all the subjects who participated in the study. We are also grateful for the 280 
help provided by Hilde Einerkjær, Marianne M. Voll and Gro E. Paulsboe at the Laboratory at 281 
Sunnaas Rehabilitation Hospital. Financial support was provided from the Throne Holst 282 
Foundation. CB and EF were also supported by the University of Ferrara (FAR2016). 283 
 284 
Conflict of interest statement  285 
The authors declare no conflict of interest. 286 
 287 
Authors’ contributions 288 
EK was responsible for designing the study, collecting data and interpreting them and writing 289 
the paper. 290 
EF was responsible for analyzing data and interpreting them and writing the paper. 291 
MS was responsible for interpreting data and writing the paper. 292 
AD was responsible for designing the study, interpreting data and writing the paper. 293 
PMS was responsible for designing the study, interpreting data and writing the paper. 294 
MCM was responsible for analyzing data and writing the paper. 295 
GS was responsible for interpreting data and writing the paper. 296 
BØ was responsible for analyzing data and interpreting them and writing the paper. 297 
CB was responsible for analyzing data and interpreting them and writing the paper. 298 
POI was responsible for designing the study, interpreting data and writing the paper. 299 
 300 
Text summary supplementary data file 301 
mRNA expression levels of Per1, Per2, Rev-Erbα, Bmal1, CDk4 and s18 measured at 07:00 302 
(time = 1), 22:00 (time = 2), 04:00 (time =3) and 07:00 (time = 4) h. Melatonin (group = 3) or 303 
15 
 
placebo (group = 4) where given to the tetraplegia group, the able-bodied slept (group = 1) or 304 






1. Reppert SM, Weaver DR. Molecular analysis of mammalian circadian rhythms. Ann 309 
Rev Physiol 2001;63:647-676. 310 
2. Mohawk JA, Green CB, Takahashi JS. Central and peripheral circadian clocks in 311 
mammals. Ann Rev Neurosci 2012;35:445-462. 312 
3. Bjarnason GA, Jordan R. Rhythms in human gastrointestinal mucosa and skin. 313 
Chronobiol Int 2002;19:129-140. 314 
4. Takata M, Burioka N, Ohdo S, Takane H, Terazono H, Miyata M, et al. Daily 315 
expression of mRNAs for the mammalian Clock genes Per2 and clock in mouse 316 
suprachiasmatic nuclei and liver and human peripheral blood mononuclear cells. Jap J 317 
Pharmacol 2002;90:263-269. 318 
5. Boivin DB, James FO, Wu A, Cho-Park PF, Xiong H, Sun ZS. Circadian clock genes 319 
oscillate in human peripheral blood mononuclear cells. Blood 2003;102:4143-4145. 320 
6. Kusanagi H, Hida A, Satoh K, Echizenya M, Shimizu T, Pendergast JS, et al. 321 
Expression profiles of 10 circadian clock genes in human peripheral blood 322 
mononuclear cells. Neurosci Res 2008;61:136-142. 323 
7. Kostovski E, Dahm AE, Mowinckel MC, Stranda A, Skretting G, Osterud B, et al. 324 
Circadian rhythms of hemostatic factors in tetraplegia: a double-blind, randomized, 325 
placebo-controlled cross-over study of melatonin. Spinal Cord 2015;53:285-290. 326 
8. Verheggen RJ, Jones H, Nyakayiru J, Thompson A, Groothuis JT, Atkinson G, et al. 327 
Complete absence of evening melatonin increase in tetraplegics. FASEB J 2012; 328 
26:3059-3064. 329 
9. Zeitzer JM, Ayas NT, Shea SA, Brown R, Czeisler CA. Absence of detectable 330 
melatonin and preservation of cortisol and thyrotropin rhythms in tetraplegia. J Clin 331 
Endocrinol Metab 2000;85:2189-2196. 332 
17 
 
10. James FO, Boivin DB, Charbonneau S, Belanger V, Cermakian N. Expression of 333 
clock genes in human peripheral blood mononuclear cells throughout the sleep/wake 334 
and circadian cycles. Chronobiol Int 2007;24:1009-1034. 335 
11. Grivas TB, Savvidou OD. Melatonin the "light of night" in human biology and       336 
adolescent idiopathic scoliosis. Scoliosis. 2007;2:6. 337 
12. Iversen PO, Dahm A, Skretting G, Mowinckel MC, Stranda A, Osterud B, et al.         338 
Reduced peak, but no diurnal variation, in thrombin generation upon melatonin 339 
supplementation in tetraplegia. A randomised, placebo-controlled study. Thromb  340 
Haem 2015;114(5). 341 
13. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time 342 
quantitative PCR and the 2-ΔΔCT method. Methods 2001;25:402-408. 343 
14. Kirshblum SC, Burns SP, Biering-Sorensen F, Donovan W, Graves DE, Jha A, et al. 344 
International standards for neurological classification of spinal cord injury. J Spinal 345 
Cord Med 2011;34:535-546. 346 
15. Gibson AE, Buchholz AC, Martin Ginis KA. C-Reactive protein in adults with chronic 347 
spinal cord injury: increased chronic inflammation in tetraplegia vs paraplegia. Spinal 348 
Cord 2008;46:616-621. 349 
16. Acuna-Castroviejo D, Rahim I, Acuna-Fernandez C, Fernandez-Ortiz M, Solera-Marin        350 
J, Sayed RKA, et al. Melatonin, clock genes and mitochondria in sepsis. Cell Mol Life 351 
Sci. 2017;74(21):3965-87. 352 
17. Russcher M, Chaves I, Lech K, Koch BC, Nagtegaal JE, Dorsman KF, et al. An 353 
observational study on disturbed peripheral circadian rhythms in hemodialysis patients. 354 
Chronobiol Int 2015;32:848-857. 355 
18 
 
18. Rana S, Munawar M, Shahid A, Malik M, Ullah H, Fatima W, et al. Deregulated 356 
expression of circadian clock and clock-controlled cell cycle genes in chronic 357 
lymphocytic leukemia. Mol Biol Rep 2014;41:95-103. 358 
19. Kavcic P, Rojc B, Dolenc-Groselj L, Claustrat B, Fujs K, Poljak M. The impact of 359 
sleep deprivation and nighttime light exposure on clock gene expression in humans. 360 
Croatian Med J 2011;52:594-603. 361 
20. Ackermann K, Plomp R, Lao O, Middleton B, Revell VL, Skene DJ, et al. Effect of 362 
sleep deprivation on rhythms of clock gene expression and melatonin in humans. 363 
Chronobiol Int 2013;30:901-909. 364 
21. Jung-Hynes B, Huang W, Reiter RJ, Ahmad N. Melatonin resynchronizes 365 
dysregulated circadian rhythm circuitry in human prostate cancer cells. J Pineal Res 366 
2010;49:60-68. 367 
22. Garstang SV, Miller-Smith SA. Autonomic nervous system dysfunction after spinal 368 
cord injury. Phys Med Rehabil Clin N Am 2007;18:275-296. 369 
23. Popa C, Popa F, Grigorean VT, Onose G, Sandu AM, Popescu M, et al. Vascular 370 
dysfunctions following spinal cord injury. J Med Life 2010;3:275-285. 371 
24. Grimaldi B, Nakahata Y, Kaluzova M, Masubuchi S, Sassone-Corsi P. Chromatin 372 
remodeling, metabolism and circadian clocks: the interplay of CLOCK and SIRT1. Int 373 
J Biochem & Cell Biol 2009;41:81-86. 374 
25. Scheer FA, Zeitzer JM, Ayas NT, Brown R, Czeisler CA, Shea SA. Reduced sleep 375 
efficiency in cervical spinal cord injury; association with abolished night time 376 
melatonin secretion. Spinal Cord 2006;44:78-81. 377 
26. Biering-Sorensen F, Biering-Sorensen M. Sleep disturbances in the spinal cord injured: 378 
an epidemiological questionnaire investigation, including a normal population. Spinal 379 
Cord 2001;39:505-513. 380 
19 
 
27. Jakimovska VM, Kostovski E, Biering-Sorensen F, Lidal IB. Psychological distress 381 
and user experiences with health care provision in persons living with spinal cord 382 
injury for more than 20 years. Spinal Cord 2017;55:864-869. 383 
28. Groah SL, Weitzenkamp DA, Lammertse DP, Whiteneck GG, Lezotte DC, Hamman 384 
RF. Excess risk of bladder cancer in spinal cord injury: evidence for an association 385 
between indwelling catheter use and bladder cancer. Arch Phys Med Rehabil 386 
2002;83:346-351. 387 
29. Slattery ML. Physical activity and colorectal cancer. Sports Med 2004;34:239-252. 388 
30. Lemoine P, Zisapel N. Prolonged-release formulation of melatonin (Circadin) for the   389 
treatment of insomnia. Expert Opin Pharmacother. 2012;13(6):895-905. 390 
31. Azama T, Yano M, Oishi K, Kadota K, Hyun K, Tokura H, et al. Altered expression 391 
profiles of clock genes hPer1 and hPer2 in peripheral blood mononuclear cells of 392 
cancer patients undergoing surgery. Life Sci 2007;80:1100-1108. 393 
 394 
  395 
20 
 
Figure legends 396 
Fig. 1 a. Experimental protocol, males with tetraplegia. Blood samples, collected 4 times over 397 
a continuous 24 h period beginning on experimental day 4 and 8, were assayed for their 398 
melatonin concentration and for the expression of clock genes in PBMCs. Crossover from 399 
placebo or melatonin were scheduled to experimental day 5. At the start of the study, 400 
participants lived on their habitual sleep/wake schedule. Wake episodes were spent in normal 401 
indoor light intensities, and sleep episodes took place in darkness. 402 
 403 
Fig. 1 b. Experimental protocol, able-bodied males. Blood samples, collected 4 times over a 404 
continuous 24 h period beginning on experimental day 1 and 16 (with a 14 days crossover 405 
time) were assayed for their melatonin concentration and for the expression of clock genes in 406 
PBMCs. At the start of the study, participants lived on their habitual sleep/wake schedule. 407 
Wake episodes were spent in normal indoor light intensities, and sleep episodes took place in 408 
darkness. 409 
 410 
Fig. 2 Plasma melatonin concentrations (pg/ml) in the four study groups during the 24-h 411 
observation period. Values are means (SEM). Melatonin or placebo where given orally to the 412 
tetraplegia group every night at 22:00 h for four continuous days before blood sampling. 413 
Melatonin was measured at 07:00, 22:00, 04:00 and 07:00 h during the 24-h observation 414 
period. The able-bodied males slept (from 23:00 to 07:00 h) or were kept awake during the 415 
24-h observation period. SCI-spinal cord injured. 416 
   417 
Fig. 3. Overall mRNA expression levels of the clock genes in PBMCs during the 24-h 418 
observation period. Values are means (±SEM). The expression of a gene in each sample was 419 
scaled to a mean expression of the same gene in all samples (AU / AUmean) and presented as 420 
21 
 
scaled AU units. a: Spinal cord injured (melatonin); b: Spinal cord injured (placebo); c: Able-421 
bodied males (awake) and d: Able-bodied males (sleeping). The mRNA expression levels 422 
were measured at 07:00, 22:00, 04:00 and 07:00 h during the 24-h observation period. 423 
Melatonin or placebo where given orally to the tetraplegia group every night at 22:00 h for 424 
four continuous days before blood sampling. The able-bodied males slept (from 23:00 to 425 
07:00 h) or were kept awake during the 24-h observation period.  426 
 427 
 428 
Fig. 4. Comparison of genes among groups, mRNA expression levels of the clock genes in 429 
PBMCs during the 24-h observation period. Values are means (±SEM). Gene expression was 430 
calculated using the 2- ∆∆Ct methods and presented as arbitrary units (AU). a: Per1; b: Per2; c: 431 
Rev-Erbα, and d: Bmal1. The mRNA expression levels were measured at 07:00, 22:00, 04:00 432 
and 07:00 h during the 24-h observation period. Melatonin or placebo where given orally to 433 
the tetraplegia group every night at 22:00 h for four continuous days before blood sampling. 434 
The able-bodied males slept (from 23:00 to 07:00 h) or were kept awake during the 24-h 435 
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